Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biotech Acquisition Company Cl A (BIOT)

Biotech Acquisition Company Cl A (BIOT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 291,812
  • Shares Outstanding, K 28,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,860 K
  • 60-Month Beta -0.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BIOT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.10 +0.50%
on 01/04/23
10.34 -1.84%
on 01/17/23
+0.05 (+0.50%)
since 12/30/22
3-Month
9.99 +1.60%
on 11/07/22
10.34 -1.84%
on 01/17/23
+0.15 (+1.50%)
since 11/02/22
52-Week
8.30 +22.29%
on 05/26/22
10.41 -2.50%
on 06/08/22
+0.29 (+2.94%)
since 02/02/22

Most Recent Stories

More News
Astrea Bioseparations to Combine with Biotage AB, Creating Global Chromatography Leader

/PRNewswire/ -- Gamma Biosciences ("Gamma"), a global life sciences platform formed by KKR to address the advanced therapy market with best-in-class...

KKR : 92.59 (-0.81%)
BIOT : 10.15 (-0.78%)
Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

/PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in...

BIOT : 10.15 (-0.78%)
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D.,...

BIOT : 10.15 (-0.78%)
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

/PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced new data from preclinical studies...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced encouraging data from phase...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced...

BIOT : 10.15 (-0.78%)
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the company will present...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the successful...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced positive topline...

BIOT : 10.15 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar